Jump to page content Accessibility
News, views and contacts from the global Drugdevelopment industry
Login to drugdevelopment-technology.com Log in or Register
  • Home
  • Products & Services
  • Company A - Z
  • Projects
  • Features
  • Videos
  • White Papers
  • News
  • Events
  • Advertise With Us
Industry Projects | Projects by Region | Projects by Category | Archived Projects | Project Gallery
 

BG-12 for the Treatment of Relapsing-Remitting Multiple Sclerosis, United States of America



The damaged MS lesion.


  • Multiple sclerosis (MS) is caused when myelin insulation gets damaged.

  • Macrophages in the area of the lesion in an MS patient.

  • The damaged MS lesion.

Back to Project Details



Related Projects

Fablyn (Lasofoxifene) - Investigational SERM
The product of a joint development programme between Pfizer and...

Exanta - Oral Direct Thrombin Inhibitor for the
Exanta (ximelagatran) is an oral Direct Thrombin Inhibitor (DTI)...

Lipitor / Torcetrapib - Combination Therapy
Under development by Pfizer, torcetrapib is a member of the cholesteryl...

Acomplia (Rimonabant) - Investigational Agent for
Developed by Sanofi-Aventis, Acomplia (rimonabant) is a selective...

Erbitux (Cetuximab)
Erbitux is a chimaeric monoclonal antibody (MAb) that is specific for...

See all projects


Contact us
Advertise with us
Terms and conditions
Privacy
Links
Newsletter sign up
Online magazine sign up

drugdevelopment-technology.com is a product of Net Resources International. Copyright 2011 Net Resources International, a trading division of SPG Media Limited.